November 22, 2024

Election Implications for Telehealth, Health Equity, AI and Life Sciences

In this article:

Healthcare Priorities: The Biden Administration emphasized health equity, AI oversight, Medicare/Medicaid access, and drug pricing through HHS initiatives, while the incoming Trump Administration is expected to roll back many of these policies, focusing on deregulation and innovation.
Telehealth Expansion: Telehealth utilization grew significantly during COVID-19, with bipartisan support for extending flexibilities, including a DEA rule allowing remote prescribing of controlled substances through 2025.
AI Regulation Shift: Biden’s executive order established AI standards and safety programs, but the Trump Administration is likely to repeal these efforts, emphasizing innovation and reducing government oversight while maintaining privacy and patient protection.
Health Equity Adjustments: The incoming administration plans to scale back DEI initiatives, shifting focus toward rural healthcare and population-based programs, while likely reversing Biden’s diversity action plans for clinical trials.
Life Sciences Focus: The Trump Administration may revisit FDA drug approval processes, evaluate user fee programs, and modify Medicare pathways like the TCET rule, impacting drug pricing and breakthrough device coverage.
Click the link to read more details

Contact Expert Request Form